1990-1999

1990-1999

Tabar L, Chen HH, Duffy SW, Krusemo UB: Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening.  Jpn J Clin Oncol. 1999 Dec;29(12):608-16. 

Tabár L, Duffy SW:  Criticism of Swedish Mammography Trials Were Wrong.  BMJ, Vol 19, 20 November 1999. pp1367 

Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabár L et al:  10-Year Results After Sector Resection With or Without Postoperative Radiotherapy for Stage 1 Breast Cancer: A Randomized Trial.  Journal of Clinical Oncology, Vol 17, No 8 (August), 1999: pp 2326-2333 

Tabár L.  Mammography saves life through early intervention in the natural course of breast cancer.  Lakartidningen. 1999 Apr 21;96(16):1943. Swedish 

Tabár L.  Assessment of the effect of mammographic screening can not be based on wrong data  Lakartidningen. 1999 Apr 7;96(14):1763-4. Swedish. 

Tabár L, Vitak B, Chen HH, Prevost TC, Duffy SW:  Update of the Swedish Two-County Trial of breast Cancer Screening: histologic grade- specific and age-specific results.  Swiss Surg 1999;5:199-204 

Duffy SW, Tabár L, Smith RA, Krusemo UB, Prevost TC, Chen HH:  Risk of Breast Cancer and Risks with Breast Cancer: the relationship between histological type and conventional risk factors, disease progression, and survival.  Seminars in Breast Disease, Vol 2, No. 4, December 1999, pp 292-300. 

Tabár L, Duffy SW, Vitak B, Chen HH, Prevost:  The Natural History of Breast Carcinoma: What have we learned from screening?  Cancer 1999; Vol 86, Number 3, pp 449-462. 

Tabár L, Chen HH, Duffy SW, Krusemo UB:  Primary and Adjuvant Therapy, Prognostic Factors and Survival in 1053 Breast Cancers Diagnosed in a Trial of Mammography Screening.  Jpn J Clin Oncol 1999; 29(12)608-616. 

Gram IT, Funkhouser E, L Tabár:  Moderate Physical Activity in Relation to Mammographic Patterns.  Cancer Epidemiology, Biomarkers & Prevention 1999;Vol 8, pp 117-122.47 

Chen HH, Thurfjell E, Duffy SW, L Tabár:  Evaluation by Markov chain models of a non-randomised breast cancer Screening programme in women aged under 50 years in Sweden .  J Epidemiol Community Health 1998;52:39-335. 

Gram IT, E Funkhouser and L Tabár:  Anthropometric indices in relation to mammographic patterns among perimenopausal women.  Int J of Cancer. 1997;73:323-326 

Duffy SW, Day NE, Tabár L, Chen HH, Smith RA:  Markov Models of Breast Tumor Progression: Some Age-specific Results.  Journal of the National Cancer Institute Monographs. 1997;No 22, 93-97 . 

Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell F, Tabár L, Nyström L:  Updated Overview of the Swedish Randomized Trials on Breast Cancer Screening With Mammography: Age Group 40 – 49 at Randomization.  Journal of the National Cancer Institute Monographs. 1997;No. 22, 57 – 61. 

Tabár L, Chen HH , Fagerberg G, Duffy SW , Smith RA:  Recent results from the Swedish Two-County Trial: the effect of age, histologic type and mode of detection on the efficacy of Breast cancer screening.  Journal of the National Cancer Institute Monographs. 1997;No 22, 43-49. 

Chen HH, Duffy SW, Tabár L:  A mover-stayer mixture of Markov chain models for the assessment of dedifferentiation and tumour progression in breast cancer.  Journal of Applied Statistics, 1997, 24:(3), 265-278. 

Liljegren G, A Lindgren, J Bergh, H Nordgren, L Tabár, L Holmberg:  Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy.  Annals of Oncology 1997;8:235-241. 

Smart C R, Mettlin CP, Tabár L, Eyre HJ:  Cancer Screening and Early Detection. pp 511-530. In:  Cancer Medicine, 4th Edition. Ed. Holland J, Bast RC, Morton DL, Frei E, Kufe DW, Weichelbaum RR. Williams & Wilkins, 1997. 

Tabár L, Gad A, Parsons W, Neeland DB:  Mammographic Appearances of in Situ Carcinomas. In: Ductal Carcinoma in Situ of the Breast pp 95 – 117 ED.: Siverstein, MJ. Williams & Wilkins. 1997. 

Chen HH, Duffy SW, Tabár L, Day NE:  Markov chain models for progression of breast cancer. Part II: prediction of outcomes for different screening regimes.  J. Epid and Biostatistics, 1997;2:(1), 25-35. 

Chen HH, Duffy SW, Tabár L, Day NE:  Markov chain models for progression of breast cancer, Part I: tumour attributes and the preclinical screen-detectable phase.  J. Epid and Biostatistics 1997;2:(1), 9-23. 

Liljegren G, Lindgren A, Bergh J, Nordgren H, Tabar L, Holmberg L. 

Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. 

Ann Oncol. 1997 Mar;8(3):235-41. 

Gram IT, Funkhouser E, Tabar L.  Anthropometric indices in relation to mammographic patterns among peri-menopausal women.  Int J Cancer. 1997 Nov 4;73(3):323-6. 

Gram IT, E Funkhouser , L Tabár:  The Tabár classification of mammographic parenchymal patterns.  Eur J. Radiology 1997;24:131-136. 

Duffy SW, Chen HH, Tabár L, Fagerberg G, Paci E:  Sojourn Time, Sensitivity, and Positive Predictive Value of Mammography Screening of Breast Cancer in Women aged 40-49.  Int. J. Epidemiol. 1996;25:1139-1145. 

Larsson LG, Nyström L, Wall S, Rutqvist LE, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L:  The Swedish randomised mammography screening trials: analysis of their effect on the breast cancer related excess mortality.  J. Medical Screening, 1996;3:(3), 129-132. 

Nyström L, Larsson LG, Wall S, Rutqvist RE, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L:  An overview of the Swedish randomised mammography trials: total mortality pattern and the representivity of the study cohorts.  J. Medical Screening, 1996;3:(2), 85-87. 

Chen HH, Duffy SW, Tabár L:  A Markov chain method to estimate the tumour progression rate from preclinical phase, sensitivity and positive predictive value for mammography in breast cancer screening.  The Statistician 1996;45:(3), 307-317. 

Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A.  Tumour development, histology and grade of breast cancers: prognosis and progression.  Int J Cancer. 1996 May 16;66(4):413-9.

Tabár L:  Mammografins förmåga finna högriskfallen är nyckelfrågan. (In Swedish).  Läkartidningen 1996;93:(38), 3221. 

Tabár L, Duffy SW, Chen HH:  Age-specific mortality reductions in the Swedish Two-County Trial of breast screening.  Letter to Editor, JNCI 1996;88:(1). 

Day NE, Tabár L, Duffy SW, Chen HH:  Population breast-cancer screening. Letter to the Editor.  The Lancet, April 1 1995;345. 

Day NE, Duffy SW, Tabár L:  Letter to the editor. Surrogate markers in cancer trials.  Statistics in Medicine 1995;14. 

Duffy SW, Tabár L:  Screening for breast cancer. Letter to Editor.  The Lancet 1995;346:852. 

Tabár L, Fagerberg G, Chen HH, Duffy SW, Gad A:  Tumor development, histology and grade of breast cancers: Prognosis and progression.  Int. J. Cancer 1996;66:413-419. 

Tabar L.  The results of mammography must be interpreted correctly even in a debate  Lakartidningen. 1995 Aug 23;92(34):2980. Swedish. 

Tabár L:  SBUs aktuella statistik inaktuell. (In Swedish).  Läkartidningen. 1995;92:(48), 4540. 

Duffy SW, Chen HH, Tabár L, Day NE:  Estimation of mean sojourn time in breast cancer screening using Markov-chain model of both entry to and exit from the preclinical detectable phase.  Statistics in Medicine. 1995;14:1531-1543. 

Tabár L:  Editorial  J Medical Screening. 1995;2:179. 

Tabár L, Fagerberg G, Chen HH, Duffy SW, Gad A:  Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality and histology.  J. Medical Screening 1995;2:94-98. 

Tabár L, Fagerberg G, Chen HH, Duffy SW, Smart C, Gad A, Smith RA:  Efficacy of Breast Cancer Screening by Age: New Results from the Swedish Two-County Trial.  Cancer 1995;75:2507-17. 

Chen HH, Tabár L, Fagerberg G, Duffy SW:  Effect of breast screening after age 65.  J. Med Screening, 1995;2:10-14. 

Gram I, Funkhouser E, Tabár L:  Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women.  British Journal of Cancer. 1995 No 71, 647-650. 

Nyström L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, Andersson I,Bjurstam N, Fagerberg G, Frisell J, Tabár L:  Determination of cause of death among breast cancer cases in the Swedish randomised mammography screening trials. A comparison between official statistics and validation by an end point committee.  Acta Oncol, 1995;34:(2), 145-452. 

Tabár L, Dean PB:  Breast cancer: A progressive, heterogeneous disease requiring multidisciplinary diagnosis and treatment.  J. Oncology Management. 1994;3(6), 12-13. 

Parker S, Burbank F, Jackman R, Aucreman S, Cardenosa G, Cink T, Coscia J, Eklund GW, Evans III WO, Garver P, Gramm H, Haas D, Jacob R, Relly R, Rillebrew L, Lechner M, Perlman S, Smid A, Tabár L, Taber F, Wynn R:  Percutaneous Large-Core Breast Biopsy: A multi-institutional study.  Radiology, 1994;193:(2), 359-364. 

Thurfjell E, Taube A, Tabár L:  One- versus two-view mammography screening.  Acta Radiologica 1994;35:340-344. 

Duffy SW, Tabár L.  Breast cancer: have we missed the forest because of the tree?  Lancet. 1994 Oct 29;344(8931):1236. 

Nyström L, Rutqvist LE, Wall S, Lindgren A, Linqvist M, Rydén S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L, Larsson LG:  Breast cancer screening with mammography: overview of the Swedish randomised trials.  Lancet 1993;341:973-978. 

Tabár L, Duffy SW, Warren Burhenne L:  New Swedish Breast Cancer Detection Results for Women Aged 40-49.  Cancer, 1993;72:1437-1448. 

Tabár L, Fagerberg G, Day NE, Duffy SW:  The Swedish two-county trial of mammographic screening for breast cancer: recent results on mortality and tumor characteristics.  Pathol. Biol (Paris) 1992;39:(9), 846. 

Tabár L, Fagerberg G, Day NE, Duffy SW, Kitchin RM:  Natural history of breast cancer: letter.  Lancet 1992;339:(8801), 1108. 

Tabár L, Fagerberg G, Day NE, Duffy SW, Kitchin RM:  Breast cancer treatment and natural history: new insights from results of screening.  Lancet 1992, Febr 15;339(8790): 412-414. 

Tabár L, Fagerberg G, Duffy SW, Day NE, Gad A, Gröntoft O:  Update of the Swedish two-county program of mammographic screening for breast cancer.  Radiol Clin. North Am. 1992;30(1), 187-210. 

Duffy SW, Tabár L, Fagerberg G, Gad A, Gröntoft O, South MC, Day NE:  Breast screening, prognostic factors and survival – results from the Swedish two-county study.  Br. J. Cancer 1991;64:(6), 1133-1138. 

Tabar L.  The term early breast cancer is misleading  Lakartidningen. 1991 Nov 20;88(47):3996. Swedish 

Tabár L, Dean PB:  Breast cancer screening; letter; comment.  Comment on: Med. J. Aust. 1991;3;154:(11), 781-782. 

Tabár L, Fagerberg CJG, South MC, Day NE, Duffy SW:  The Swedish Two-County Trial of Mammographic Screening for Breast Cancer: Recent Results on Mortality and Tumour Characteristics.  Cancer Screening Eds.: AB Miller, J Chamberlain, N E Day, et al. Cambridge Univ Press UICC Public. 

Tabár L, Duffy SW, Day NE:  Screening with mammography: letter. Int.  J. Technol Assess Health Care 1990;6(3), 498-500 

Tabár L, Dean PB:  Calidad de la mammografia en screening. Focus, 1990;1:39-40. 

Alveryd, Andersson I, Aspegren K, Balldin G, Bjurstam N, Edström G, Fagerberg G, Glas U, Jarlman O, Larsson S, Lindbrink B, Lingaas H, Löfgren M, Rudenstam CM, Strender L, Samuelsson L, Tabár L, Taube A, Wallberg H, Åkesson P, Hallberg D:  Lightscanning versus mammography for the detection of breast cancer in screening and clinical setting.  Cancer, 1990; 65: 1671-77. 

Tabár L, Fagerberg G, Duffy SW, Day NE:  WE-Projektet: mammografi minskar dödligheten i bröstcancer signifikant. (In Swedish).  Läkartidningen, 1990;87:(1-2), 36-9. 

Haus A G, Feig SA, Ehrilich SM, Hendrick RE, Tabár L:  Mammography Screening: Technology, Radiation Dose and Risk, Quality Control, and Benefits to Society.  Radiology, 1990;174(3), 627-656. 

Rutqvist LE, Miller AB, Andersson I, Hakama M, Hakulinen T, Sigfusson BF, Tabar L:  Reduced breast-cancer mortality with mammography screening–an assessment of currently available data. Int J Cancer Suppl. 1990;5:76-84. Review. 

Tabár L:  Control of breast cancer through screening mammography.  Radiology, 1990;174:(3 Pt 1), 655-6.